Mediscience pros & cons

Market watchers had mixed reactions to last week's announcement by the London Stock Exchange that it had formed the techMARK mediscience Index to track the performance of 48 LSE-listed healthcare companies, including therapeutic, diagnostic, drug delivery and specialty pharma plays. The main divide was between those

Read the full 462 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE